Mindray Launches New TE7 ACE Point-of-Care Solution

Mindray Medical has announced the release of a new point-of-care ultrasound system. The TE7 ACE is a new touch screen ultrasound system that provides targeted solutions to diverse point-of-care scenarios including: anesthesia, critical care and emergency. Featuring...

Hitachi Healthcare Americas Plans Innovation Center

Hitachi Healthcare Americas has announced that it will create a new dedicated research and development facility within its North American headquarters facility in Twinsburg, Ohio. The move will result in the creation of approximately 40 new jobs, adding to the nearly...

Acertara R&D Team Receives Another Patent

Acertara Acoustic Laboratories, an independent ISO/IEC 17025:2017 accredited medical ultrasound acoustic measurement, testing, and calibration laboratory, and ISO13485:2016 certified probe repair and new product development facility announces their Research and...

Conquest Imaging Expands SIMPLIFY Program

Conquest Imaging has announced the expansion of SIMPLIFY, Conquest Imaging’s transducer repair program, featuring added TEE probe repair capabilities, flat rate repair pricing and a mobile probe testing program. The entire SIMPLIFY program is overseen by Vice...

GE Healthcare LOGIQ E10

The LOGIQ E10 ultrasound system integrates Artificial Intelligence, advanced tools and enhanced workflow capabilities to enable clinicians to scan, diagnose and treat a wide range of patients across a broad spectrum of conditions. One of its newest applications, Breast Assistant, powered by Koios DS, automatically provides an AI-based quantitative risk assessment that aligns to a BI-RADS category. During an exam, if a technician spots a suspicious area in the breast image, after contouring the lesion, the technician clicks the Breast Assistant button on the console, and the AI tool automatically analyzes the lesion, generating a BI-RADS-aligned category and risk assessment within two seconds or less. The color-coded scale aligns to the likelihood of malignancy – in essence helping to “dial in” the BI-RADS assessment, to support the clinician’s decision-making.



Submit a Comment

Your email address will not be published. Required fields are marked *